{"drugs":["Epoetin Theta"],"mono":{"0":{"id":"930419-s-0","title":"Generic Names","mono":"Epoetin Theta"},"1":{"id":"930419-s-1","title":"Dosing and Indications","sub":[{"id":"930419-s-1-4","title":"Adult Dosing","mono":"<ul><li>epoetin theta has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li>continue same route of administration when switching to or from another epoetin product<\/li><li><b>Anemia due to chemotherapy - Cancer, Non-myeloid:<\/b> initial, 20,000 international units SUBQ once weekly; if Hb increases by at least 1 g\/dL (0.62 mmol\/L) after 4 weeks, continue same dose; if Hb not increased by at least 1 g\/dL after 4 weeks, increase to 40,000 international units SUBQ once weekly; if Hb not increased by at least 1 g\/dL after 4 weeks at a dose of 40,000 international units\/week, increase the dose to 60,000 international units SUBQ once weekly; if Hb not increased by at least 1 g\/dL after 12 weeks, discontinue therapy; target Hb (10 g\/dL (6.21 mmol\/L) to 12 g\/dL (7.45 mmol\/L); MAX dose, 60,000 international units SUBQ once weekly; continue therapy up to 4 weeks after end of chemotherapy<\/li><li><b>Anemia of chronic renal failure:<\/b> (correction phase) initial, 20 international units\/kg SUBQ or 40 international units\/kg IV 3 times per week; if Hb level inadequate (increase less than 1 g\/dL (0.62 mmol\/L)) after 4 weeks, may increase to 40 international units\/kg SUBQ or to 80 international units\/kg IV 3 times per week; at monthly intervals, continue dose increases by 25% of previously administered dose until target Hb obtained (10 g\/dL (6.21 mmol\/L) to 12 g\/dL (7.45 mmol\/L); MAX dose, 700 international units\/kg\/week SUBQ or IV (European Medicines Agency-approved dosing)<\/li><li><b>Anemia of chronic renal failure:<\/b> (maintenance phase) adjust dose by approximately 25% to maintain target Hb level (10 g\/dL (6.21 mmol\/L) to 12 g\/dL (7.45 mmol\/L)); administer SUBQ 3 times per week or administer total weekly dose SUBQ once per week; if Hb stable at IV dose frequency of 3 times per week, reduce frequency to 2 times per week; at monthly intervals, continue dose increases by 25% of previously administered dose to maintain target Hb level; MAX dose, 700 international units\/kg\/week SUBQ or IV (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"930419-s-1-5","title":"Pediatric Dosing","mono":"no experience in children and adolescents "},{"id":"930419-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hematologic:<\/b> anemia of chronic renal failure with or without the presence of hypertension or existing cardiovascular, cerebrovascular, or peripheral vascular disease, avoid Hb increase greater than 2 g\/dL (1.24 mmol\/L) over a 4-week period; if Hb increases more than 2 g\/dL over 4 weeks or if Hb is greater than 12 g\/dL (7.45 mmol\/L), reduce dose by 25% to 50%; if Hb continues to increase, interrupt therapy until Hb begins to decrease and restart at dose approximately 25% lower than previously administered dose<\/li><li><b>hematologic:<\/b> chemotherapy-induced anemia in patients with non-myeloid malignancies, if Hb increases more than 2 g\/dL (1.24 mmol\/L) in 4 weeks or Hb is greater than 12 g\/dL (7.45 mmol\/L), reduce dose by 25% to 50%; if Hb is greater than 13 g\/dL (8.07 mmol\/L), interrupt therapy until Hb decreases to less than 12 g\/dL and restart at a dose approximately 25% lower than previously administered dose<\/li><\/ul>"},{"id":"930419-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><ul><li>Anemia due to chemotherapy - Cancer, Non-myeloid<\/li><li>Anemia of chronic renal failure<\/li><\/ul>"}]},"3":{"id":"930419-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930419-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to epoetin theta or any component of the product or to other epoetins<\/li><li>hypertension, uncontrolled<\/li><\/ul>"},{"id":"930419-s-3-10","title":"Precautions","mono":"<ul><li>hypertension, new-onset or aggravation of preexisting, has occurred, particularly during initial treatment phase; monitor and control blood pressure before and during therapy, with adjustment or addition of antihypertensive medication as necessary; epoetin theta dose adjustment or temporary interruption with reinitiation at a reduced dose may be required<\/li><li>hypertensive crisis with encephalopathy-like symptoms may occur, even in patients with normal or low blood pressure; monitor and control blood pressure before and during therapy, with adjustment or addition of antihypertensive medication as necessary; epoetin theta dose adjustment or temporary interruption with reinitiation at a reduced dose may be required <\/li><li>misuse by healthy persons may lead to an excessive increase in Hb and HCT, which may be associated with life-threatening cardiovascular complications<\/li><li>pure red cell aplasia due to neutralizing anti-erythropoietin antibodies has been reported; do not switch patients with suspected or confirmed neutralizing antibodies to erythropoietin to epoetin theta due to crossreactivity; discontinue treatment and perform antibody testing if decreased Hb and severe anemia with low reticulocyte counts develops<\/li><li>(chronic renal failure) clotting of the arteriovenous shunt may occur, particularly in patients with tendency for hypotension or arteriovenous fistulae complications; consider increased anticoagulation<\/li><li>(chronic renal failure) Hb greater than 12 g\/dL (7.45 mmol\/L), or an Hb increase of greater than 2 g\/dL (1.24 mmol\/L) over a 4-week period, use should be avoided; monitoring recommended; epoetin theta dose adjustment or temporary interruption with reinitiation at a reduced dose may be required<\/li><li>(chronic renal failure) nephrosclerotic patients not yet undergoing dialysis; possible accelerated progression of renal failure cannot be excluded<\/li><\/ul>"},{"id":"930419-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"930419-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"5":{"id":"930419-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension (1% to less than 10%)<\/li><li><b>Dermatologic:<\/b>Disorder of skin (1% to less than 10%)<\/li><li><b>Neurologic:<\/b>Headache (1% to less than 10%)<\/li><li><b>Other:<\/b>Influenza-like symptoms (1% to less than 10%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Arteriovenous shunt thrombosis (chronic renal failure, 1% to less than 10%), Hypertensive crisis (chronic renal failure, 1% to less than 10%), Thromboembolic disorder<\/li><li><b>Hematologic:<\/b>Pure red cell aplasia, Antibody-induced<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><\/ul>"},"6":{"id":"930419-s-6","title":"Drug Name Info","sub":{"2":{"id":"930419-s-6-19","title":"Class","mono":"<ul><li>Blood Modifier Agent<\/li><li>Erythropoietic<\/li><\/ul>"},"3":{"id":"930419-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"930419-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>subQ or IV only; supplied as single-use, prefilled syringes with or without safety device<\/li><li>do not shake prefilled syringe; allow to reach comfortable temperature (15 to 25 degrees C) prior to injection<\/li><li>do not mix with any other product<\/li><li>if substituting with another epoetin product, use same route of administration<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>subQ route preferred in patients not undergoing hemodialysis<\/li><li>subQ route recommended in cancer patients with non-myeloid malignancies receiving chemotherapy<\/li><\/ul><\/li><\/ul>"}}}